Lunit Cancer Screening @Lunit_AI

Breast imaging AI is no longer a question of “does it work?” The focus now is on how to implement it at scale in real screening environments, in a way that’s consistent, reliable, and trusted by clinicians. In this @Dx_imaging Practice Academy session, David Gruen, MD, MBA, FACR, Radiologist at Advanced Radiology Consultants and former IBM Watson Health CMO, shares how leading programs are bringing AI from evidence into everyday practice. You’ll learn how teams are: ❇️ Building clinician confidence ❇️ Integrating AI into existing workflows ❇️ Measuring impact on recalls, workload, and cancer detection If you’re moving beyond the pilot phase, this session offers a practical look at what comes next. 📅 Thurs, May 21 | 1:05 to 1:50 PM EDT 👉 Register now: registration.diagnosticimaging.com/may2026 #Lunit #medicalAI #radiologyAI #webinar

Don't miss the #AI Advances in #Radiology Webinar tomorrow with David Gruen, MD, Nancy Walker and @RajeshBhayana_ . Register now at: registration.diagnosticimaging.com/may2026?utm_so… @RadiologyACR @ARRS_Radiology @RSNA @Lunit_AI @CoronisHealth @imagingtoronto #RadRes

“More for Less” Isn’t a Theory. It’s Already happening in Breast Screening. 📰 A recent The Wall Street Journal article highlights a powerful shift in Sweden’s healthcare system: delivering more outcomes with fewer resources. At St. Göran’s Hospital in Stockholm, that shift is real—and measurable. Radiologist Karin Dembrower describes identifying cancers that “we cannot see with our eyes”…yet AI can. The result isn’t just better detection. It’s a fundamentally different operating model. Read more: wsj.com/world/europe/t…

🎉 We're thrilled to share that Lunit INSIGHT® CXR4 is now approved by Health Canada! 🇨🇦 We're proud to bring our most advanced chest X-ray AI to care teams across Canada, with features designed to support radiologists at every step: ✅ Detects 11 abnormalities across dozens of diagnoses ✅ Normal Flagging powered by DualScan System ✅ Acute Bone Fracture Detection ✅ Expanded Current-Prior Comparison 👉 Learn more about Lunit INSIGHT CXR4: lunit.io/en/ai-radiolog… #Lunit #CXR #Radiology #ChestXray #Chestscreening #Healthcanada

The latest NCCN Breast Cancer Screening & Diagnosis Guidelines (v1.2026) includes a pivotal update: image‑based risk assessment is now recognized as a valid way to identify women at increased risk of invasive breast cancer. Image-based risk is a 5-year breast cancer risk assessment approach that can be derived from routine, negative, screening mammograms. By recognizing this as complementary to traditional clinical and hereditary risk models, the NCCN guidelines introduce a new pathway of visibility into an individual’s risk of breast cancer. With this update, clinicians have a new option to support patients identified as “increased risk” with: ✅ Tailored screening strategies ✅ Additional surveillance ✅ Ongoing risk reassessment ✅ Consideration of counseling for risk reduction strategies At Lunit, we see this as an important step toward more accessible, image-driven breast cancer risk assessment. It also underscores the importance of innovations like Lunit INSIGHT Image-Based Risk – a solution designed to estimate a woman’s 5-year breast cancer risk using routine mammographic images and age. The model received FDA Breakthrough Device Designation in 2025 and is currently under 510(k) review. #Lunit #breastcancer #riskassessment #breastscreening #mammography

🩵 NCoBC 2026 wrapped up this weekend, and we're still thinking about the conversations we had there. There's something about a room full of people who have dedicated their careers to breast cancer care that puts things in perspective. This year felt especially meaningful with the conference celebrating its 35th anniversary, a testament to how far the field has come and how much further this community is committed to taking it. Brian Drohan, PhD, Medical Science Liaison at Lunit, opened Monday morning with a session on risk assessment in contemporary practice. He walked through where science is today and where it's headed. It was a great way to close out the weekend. To everyone who stopped by and connected with us, thank you! The conversations we have at events like this remind us why this work matters. 🙌 👉Couldn't make it to NCoBC? We'd love to connect and share more about how our AI solutions are supporting breast centers: lunit.io/en/contact-us/ #NCoBC #NCoBC2026 #breastcancer #AI #Lunit #riskassessment #EarlyDetection #Mammography #breastscreening

keyboard_arrow_left Previous keyboard_arrow_right Next

Screening is more than early detection. It improves survival in stage IV breast cancer. For years, mammography has been discussed mainly as a way to detect cancer early. New research in the Journal of the National Cancer Institute shows its impact reaches much further than that. A study of more than 817,000 women in Denmark found a dramatic difference in five‑year net survival for women diagnosed with Stage IV breast cancer: → Screen-detected: 74.7% → Never-screened: 32.4% This gap is not explained by lead‑time bias. Screen‑detected Stage IV cancers were more likely to be oligometastatic and far more likely to be treated surgically. 67% of screen‑detected cases were candidates for surgery, compared with 23% percent in women who were never screened. Screening doesn’t just find cancer earlier. It changes the clinical trajectory of advanced disease and expands what is treatable, even at Stage IV. As pressure on radiologists and technologists continues to increase, AI plays a growing role in supporting accuracy and consistency. These are the foundations that make life‑saving interventions possible. 🔗 Read the full study: pubmed.ncbi.nlm.nih.gov/41707694/ #breastcancer #cancer #mammography #breastscreening #Lunit

📷 What an inspiring week in Vienna! It was fantastic to connect with so many clinicians, researchers, and partners from across Europe during #ECR. Thank you for visiting us! One of the highlights of this year’s ECR was our hands-on workshops. Attendees reviewed clinical cases with AI outputs and experienced how AI can support both screening and symptomatic breast imaging in practice. We were also honored to host a symposium and share valuable perspectives from across Europe on the real-world successes, ongoing challenges, and future directions of AI adoption in screening mammography. We are very grateful to our partners at #Fujifilm for co-organizing the workshops and symposium with us! And of course, a big thank you to the Lunit team on the ground in Vienna. It was great to share such a busy and rewarding week together. 👋 We look forward to continuing the conversation and advancing AI together. See you again soon! 👀 Missed our booth at ECR? Don’t worry, we can still connect. If you’d like to learn more about our AI solutions or schedule a meeting with our team, 🔗 contact us here: lunit.io/en/contact-us/ #Lunit #ECR #medicalAI #cancersreening #radiology

keyboard_arrow_left Previous keyboard_arrow_right Next

.@Harrison_ai Continues to Grow Open #Platform Ecosystem, Welcomes Four New #AI Partners -@AIRAmed_GmbH @KoiosMed @Lunit_AI and @nanox_vision AI | #radiology businesswire.com/news/home/2026…

New #Mammography Study Suggests #AI May Predict #BreastCancer Detection in Subsequent Screening diagnosticimaging.com/view/new-mammo… @RadiologyACR @ARRS_Radiology @RSNA @BreastImaging @UABRadiology @WCMRadiology @BrighamRad @OSURadiology @PennRadiology @Lunit_AI #radiology #RadRes #ECR2026

In May last year, we established Lunit Japan Inc. to strengthen our on-the-ground presence and work even more closely with #FUJIFILM through a complementary go-to-market strategy designed to expand access and drive growth in Japan. With rising imaging demand, workforce shortages, and a high reliance on general practitioners for image interpretation, we see clear opportunities for AI to help enhance reading performance and clinical workflows. In close collaboration with FUJIFILM, the latest version of FUJIFILM’s CXR-AID, incorporating Lunit’s AI technology, has now been launched in Japan for chest screening. Since its initial release in 2021, CXR-AID has been adopted by more than 4,000 medical institutions in Japan. 🔗Read more: fujifilm.com/fms/ja/news/371 #Lunit #INSIGHTCXR #CXR #chestscreening #medicalAI #healthcareAI #Japan

We’re excited to be back in Vienna soon for #ECR2026 🇦🇹 and we’d love to meet you in person. At Lunit, we work closely with clinicians to understand what actually helps in day-to-day practice. At this year’s ECR, we’ll be sharing how our latest AI solutions for chest and breast imaging are already being used in real clinical workflows across Europe. Visit us at booth AI-10 to meet the team, see live demos, and have an open conversation about how AI can support confident image interpretation in your own environment. 👉 Book your meeting with us at ECR 2026: microsite.lunit.io/meet-lunit-at-… Experience AI built for real clinical workflows at ECR 2026! @myESR #Lunit #ECR #chestscreening #breastscreening #radiology #medicalAI

keyboard_arrow_left Previous keyboard_arrow_right Next

Italy introduces new AI screening guidelines: Redefining double-reading with AI In a major policy shift, #Italy has become the first country in Europe to recommend using AI, not just to assist with mammogram interpretation, but to intelligently triage which exams require #double_reading. Under the new national guidelines, AI is used upfront to classify mammograms by risk level: only higher-risk cases are reviewed by two radiologists, while lower-risk exams may be read by a single reader. Read the full article: en.ilsole24ore.com/art/breast-can… Our breast AI has already supported double-reading screening programs to manage workload and detect cancers earlier in Europe. 👉Discover how our AI is applied in clinical practice: lunit.io/en/media-hub/r… #Lunit #breastcancer #breastscreening #mammography #radiology

BreastScreen NSW expands AI-supported mammography reading to all first-time screeners. Following a successful rollout over the past 12 months, BreastScreen NSW has expanded machine reading technology to include mammography images from all women attending screening for the first time. 👉 Read the full article here: cancer.nsw.gov.au/what-we-do/new… 📌 The impact is clear: fewer unnecessary recalls, reduced anxiety for women, with no compromise in cancer detection. Every exam continues to be read by a radiologist, with AI providing additional analysis to support confidence and efficiency in real-world clinical workflows. Through its collaboration with Lunit, BreastScreen NSW became the world’s first nationally governed cancer screening program to integrate AI. By deploying Lunit INSIGHT MMG as a second reader, the program enhances early detection, eases radiologist workload, and helps future-proof screening services amid global workforce shortages. #Lunit #LunitINSIGHT #BreastScreening #Mammography #BreastCacner #BSNSW #Australia

🩺 Breast density shouldn’t dictate how confident a screening read can be — but today, it still has a major impact. A recent article in The Imaging Wire highlights how significantly dense breast tissue reduces mammography accuracy, even when using digital breast tomosynthesis (DBT). This growing body of evidence highlights why decision support in DBT matters more than ever — especially as density notification requirements and supplemental screening conversations expand. Lunit INSIGHT DBT is designed to support more consistent interpretation in dense breasts by providing: • AI-assisted analysis for DBT, highlighting suspicious findings across complex, multi-slice exams • Consistent performance across breast types, including both fatty and dense tissue • AI-guided navigation and workflow support that simplifies slice selection and DBT review As screening programs work to deliver confidence and consistency across diverse patient populations, tools that help radiologists navigate density-related limitations may play an increasingly important role. 👉 Read the article: Breast Density’s Impact on Mammography - The Imaging Wire 👉 Learn more about Lunit INSIGHT DBT: AI-Assisted Mammography for 3D Detection | Lunit #Lunit #BreastImaging #DenseBreasts #DBT #AIinRadiology #Mammography #RadiologyAI

The Imaging Wire @TheImagingWire

5 months ago

Imaging Wire #768 is now live theimagingwire.com/newsletter/den… Featuring… Breast Density’s Impact on Mammography CEM for Dense Breast Surveillance Racial Differences in Breast Tissue And much more…

1 0 2 272 0

We recently announced the 510(k) submission of Lunit INSIGHT Risk, our mammography-based model for predicting a woman’s five-year breast cancer risk without patient questionnaires.​ ​ But where did this breakthrough begin, and what could it mean for the future of screening? ​ ​ Dr. Graham Colditz, who co-developed the image-based risk model (formerly known as Prognosia Breast) with Prof. Shu (Joy) Jiang at Washington University, St. Louis, dives into these questions in a recent article. ​ ​ In the article, Dr. Colditz shares his vision for personalized screening, the real-world challenges they aimed to solve, and how AI-powered risk modeling could help us move beyond the limitations of traditional tools, enabling more equitable, scalable, and proactive care.​ ​ 📌 Read the full article and explore the future of precision prevention: volparahealth.com/news/the-futur… ​ #Lunit #LunitINSIGHTRisk #breastcancer #riskprediction #medicalAI #radiology #FDA

🚀 510(k) Application for Lunit INSIGHT Risk! ​ We’re excited to announce that we’ve submitted a 510(k) premarket notification to the #FDA for Lunit INSIGHT Risk – a mammography-based, five-year breast cancer #risk #prediction #model that requires no patient questionnaires.​ ​ This is the first AI solution to generate SEER-calibrated, five-year absolute risk estimates for U.S. women.​ For example, a 5% risk means 5 out of 100 women with similar profiles are expected to develop breast cancer within the next five years.​ ​ 🌟 Proven in two peer-reviewed studies!​ Lunit INSIGHT Risk has been validated in two peer-reviewed studies published in JAMA Network Open and JCO Clinical Cancer Informatics, demonstrating strong performance with AUCs up to 0.80 in the hashtag#US and hashtag#Canada. Its consistent performance across age, race, and breast density supports the potential for equitable adoption in clinical settings.​ ​ But this is more than a new model. Lunit INSIGHT Risk is designed to integrate directly with our breast AI detection tools, including Lunit INSIGHT MMG and DBT, and Volpara Risk Pathways, forming a comprehensive foundation for smarter, risk-informed breast screening.​ 🔗 Learn how Lunit INSIGHT Risk could help transform the future of breast cancer prevention: lunit.io/en/media-hub/l… ​ #Lunit #INSIGHTRisk #medicalAI #breastscreening #riskassessment #breastcancer #riskprediction

👏 RSNA 2025 – what a powerful week of connection and collaboration!​ This year, we engaged with over 19,000 medical professionals who share our vision of using AI to conquer cancer. From 14 scientific abstracts featuring Lunit and Volpara solutions to 23 expert-led presentations in the Lunit workshop session, we were proud to be part of the conversations shaping the future of radiology.​ Thank you to everyone who stopped by, shared insights, and inspired us. We’re grateful to stand alongside a community that’s passionate about advancing care and pushing innovation forward.​ Let’s keep the momentum going together! ​ 👋 Missed us at RSNA? Want to learn more about our AI solutions? Let’s connect: lunit.io/en/contact-us/ ​ #Lunit #Volpara #RSNA25 #Radiology #MedicalAI #CancerScreening

AI is no longer just assisting radiologists; it’s transforming the diagnostic ecosystem. In this interview, Lunit CEO Brandon Suh shares how AI is reshaping cancer care, what many still miss when adopting it, and what success looks like in 5 years. 🔗 Read the full interview here: volparahealth.com/news/redefinin… #Lunit #LunitAI #medicalAI #cancerscreening #breastscreening #radiology